Needham & Company LLC reiterated their hold rating on shares of Axonics (NASDAQ:AXNX – Free Report) in a research report sent to investors on Monday, Benzinga reports.
Axonics Stock Up 0.1 %
Axonics stock traded up $0.09 during trading hours on Monday, hitting $68.71. The stock had a trading volume of 396,265 shares, compared to its average volume of 844,940. The company has a 50-day moving average of $67.59 and a two-hundred day moving average of $67.72. Axonics has a fifty-two week low of $48.30 and a fifty-two week high of $69.68. The company has a market cap of $3.51 billion, a PE ratio of -214.44 and a beta of 0.83.
Axonics (NASDAQ:AXNX – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.03. The business had revenue of $114.57 million for the quarter, compared to analysts’ expectations of $112.83 million. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. Axonics’s quarterly revenue was up 23.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.15) earnings per share. As a group, analysts forecast that Axonics will post 0.13 EPS for the current fiscal year.
Institutional Trading of Axonics
Axonics Company Profile
Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.
Featured Articles
- Five stocks we like better than Axonics
- Investing in large cap stocks: Diving into big caps
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Why is the Ex-Dividend Date Significant to Investors?
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- When to Sell a Stock for Profit or Loss
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.